These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 21737454)

  • 1. Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth.
    Castonguay R; Werner ED; Matthews RG; Presman E; Mulivor AW; Solban N; Sako D; Pearsall RS; Underwood KW; Seehra J; Kumar R; Grinberg AV
    J Biol Chem; 2011 Aug; 286(34):30034-46. PubMed ID: 21737454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Activation of Bone Morphogenic Protein 9 by Receptor-mediated Displacement of Pro-domains.
    Kienast Y; Jucknischke U; Scheiblich S; Thier M; de Wouters M; Haas A; Lehmann C; Brand V; Bernicke D; Honold K; Lorenz S
    J Biol Chem; 2016 Feb; 291(7):3395-410. PubMed ID: 26677222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth.
    Mitchell D; Pobre EG; Mulivor AW; Grinberg AV; Castonguay R; Monnell TE; Solban N; Ucran JA; Pearsall RS; Underwood KW; Seehra J; Kumar R
    Mol Cancer Ther; 2010 Feb; 9(2):379-88. PubMed ID: 20124460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity and structure of a high affinity activin receptor-like kinase 1 (ALK1) signaling complex.
    Townson SA; Martinez-Hackert E; Greppi C; Lowden P; Sako D; Liu J; Ucran JA; Liharska K; Underwood KW; Seehra J; Kumar R; Grinberg AV
    J Biol Chem; 2012 Aug; 287(33):27313-25. PubMed ID: 22718755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoglin requirement for BMP9 signaling in endothelial cells reveals new mechanism of action for selective anti-endoglin antibodies.
    Nolan-Stevaux O; Zhong W; Culp S; Shaffer K; Hoover J; Wickramasinghe D; Ruefli-Brasse A
    PLoS One; 2012; 7(12):e50920. PubMed ID: 23300529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function.
    Mallet C; Lamribet K; Giraud S; Dupuis-Girod S; Feige JJ; Bailly S; Tillet E
    Hum Mol Genet; 2015 Feb; 24(4):1142-54. PubMed ID: 25312062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Basis of the Human Endoglin-BMP9 Interaction: Insights into BMP Signaling and HHT1.
    Saito T; Bokhove M; Croci R; Zamora-Caballero S; Han L; Letarte M; de Sanctis D; Jovine L
    Cell Rep; 2017 May; 19(9):1917-1928. PubMed ID: 28564608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone Morphogenetic Protein 9 Reduces Cardiac Fibrosis and Improves Cardiac Function in Heart Failure.
    Morine KJ; Qiao X; York S; Natov PS; Paruchuri V; Zhang Y; Aronovitz MJ; Karas RH; Kapur NK
    Circulation; 2018 Jul; 138(5):513-526. PubMed ID: 29487140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of a Soluble Form of Human Endoglin Fused to Green Fluorescent Protein.
    Ruiz-Llorente L; Vega MC; Fernández FJ; Langa C; Morrell NW; Upton PD; Bernabeu C
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the ALK1 ligands, BMP9 and BMP10.
    Li W; Salmon RM; Jiang H; Morrell NW
    Biochem Soc Trans; 2016 Aug; 44(4):1135-41. PubMed ID: 27528761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma.
    Tillet E; Ouarné M; Desroches-Castan A; Mallet C; Subileau M; Didier R; Lioutsko A; Belthier G; Feige JJ; Bailly S
    J Biol Chem; 2018 Jul; 293(28):10963-10974. PubMed ID: 29789425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BMP10 functions independently from BMP9 for the development of a proper arteriovenous network.
    Choi H; Kim BG; Kim YH; Lee SJ; Lee YJ; Oh SP
    Angiogenesis; 2023 Feb; 26(1):167-186. PubMed ID: 36348215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
    Upton PD; Davies RJ; Trembath RC; Morrell NW
    J Biol Chem; 2009 Jun; 284(23):15794-804. PubMed ID: 19366699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis.
    Cunha SI; Pardali E; Thorikay M; Anderberg C; Hawinkels L; Goumans MJ; Seehra J; Heldin CH; ten Dijke P; Pietras K
    J Exp Med; 2010 Jan; 207(1):85-100. PubMed ID: 20065063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BMP9 and BMP10 are critical for postnatal retinal vascular remodeling.
    Ricard N; Ciais D; Levet S; Subileau M; Mallet C; Zimmers TA; Lee SJ; Bidart M; Feige JJ; Bailly S
    Blood; 2012 Jun; 119(25):6162-71. PubMed ID: 22566602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and functional insights into endoglin ligand recognition and binding.
    Alt A; Miguel-Romero L; Donderis J; Aristorena M; Blanco FJ; Round A; Rubio V; Bernabeu C; Marina A
    PLoS One; 2012; 7(2):e29948. PubMed ID: 22347366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells.
    David L; Mallet C; Mazerbourg S; Feige JJ; Bailly S
    Blood; 2007 Mar; 109(5):1953-61. PubMed ID: 17068149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?
    Bhatt RS; Atkins MB
    Clin Cancer Res; 2014 Jun; 20(11):2838-45. PubMed ID: 24714770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of soluble endoglin in BMP9 signaling.
    Lawera A; Tong Z; Thorikay M; Redgrave RE; Cai J; van Dinther M; Morrell NW; Afink GB; Charnock-Jones DS; Arthur HM; Ten Dijke P; Li W
    Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17800-17808. PubMed ID: 31431534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N; Haba A; Matsuno F; Seon BK
    Cancer Res; 2001 Nov; 61(21):7846-54. PubMed ID: 11691802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.